NCT05568589

Brief Summary

The aim of this study: It was aimed to observe the effects of intraoperative and preoperative PECS II block on postoperative pain, amount of analgesic use and shoulder joint range of motion in patients who underwent breast cancer surgery. This research was planned as an observational study. For this purpose, patients who underwent breast cancer surgery in İzmir Bakırçay University Çiğli Training and Research Hospital General Surgery Clinic will be included in the study at the 1st hour after the operation. Patients who underwent preoperative Interpectoral - Pectoserratus Plan Block in the operation will be included in Group 1, patients who have been applied Interpectoral - Pectoserratus Plan Block between the muscle planes by the intraoperative surgeon will be included in Group 2, and patients who have not applied any block will be included in Group 3. Pain numerical rating scale (numering Rating Scale) at postoperative 1st, 2nd, 6th, 12th and 24th hours in patients, patient recovery scores (QoR15 Turkish version), amount of tramadol used in patient-controlled analgesia, time to first rescue analgesia, adverse events (pneumothorax, nausea, vomiting, itching, hematoma, allergic reactions) and quality of life, shoulder joint range of motion, hand grip strength (also on day 1) and disability level will be measured on postoperative day 10. H0- Preoperative interpectoral - pectoserratus plane block affects the level of postoperative pain. H1- Preoperativeinterpectoral - pectoserratus plane block does not affect the level of postoperative pain. H2- Intraoperative interpectoral - pectoserratus plane block affects postoperative pain level H3- Intraoperative interpectoral - pectoserratus plane blockk does not affect the level of postoperative pain.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
60

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Oct 2022

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 2, 2022

Completed
3 days until next milestone

First Posted

Study publicly available on registry

October 5, 2022

Completed
1 day until next milestone

Study Start

First participant enrolled

October 6, 2022

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 6, 2023

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

April 6, 2023

Completed
Last Updated

October 5, 2022

Status Verified

October 1, 2022

Enrollment Period

3 months

First QC Date

October 2, 2022

Last Update Submit

October 2, 2022

Conditions

Keywords

İnterpectoral plane blockPectoserratus plane blockBreast CancerPECS II Block

Outcome Measures

Primary Outcomes (1)

  • Postoperative opioid consumption

    Tramadol consumption in the first 24 hours after surgery

    24 hours

Secondary Outcomes (6)

  • NRS scores

    1., 2., 6., 12., 24. hour

  • Quality of Recovery

    24th hours

  • The disability levels of the patients due to shoulder dysfunction.

    10th day

  • Hand grip muscle strength.

    24th hour, 10th day

  • Quality of Life (Short Form 36)

    24th hour, 10th day

  • +1 more secondary outcomes

Study Arms (3)

Preoperative Interpectoral - Pectoserratus Plane Block

The block will be done by the Anesthesiologist.

Other: Preoperative Interpectoral - Pectoserratus Plane Block

Intraoperative Interpectoral - Pectoserratus Plane Block

The block will be made by the surgeon.

Other: Intraoperative Interpectoral - Pectoserratus Plane Block

Non Block

will not be blocked.

Other: Non Block

Interventions

Pain numerical rating scale (numering Rating Scale) at postoperative 1st, 2nd, 6th, 12th and 24th hours in patients, patient recovery scores at 24th hour (QoR15 Turkish version), amount of tramadol used in patient-controlled analgesia, time to first rescue analgesia , adverse events (pneumothorax, nausea, vomiting, pruritus, hematoma, allergic reactions) and hand grip strength on the postoperative 1st day, quality of life, shoulder joint range of motion, and disability level will be measured on the postoperative 10th day.

Preoperative Interpectoral - Pectoserratus Plane Block

Pain numerical rating scale (numering Rating Scale) at postoperative 1st, 2nd, 6th, 12th and 24th hours in patients, patient recovery scores at 24th hour (QoR15 Turkish version), amount of tramadol used in patient-controlled analgesia, time to first rescue analgesia , adverse events (pneumothorax, nausea, vomiting, pruritus, hematoma, allergic reactions) and hand grip strength on the postoperative 1st day, quality of life, shoulder joint range of motion, and disability level will be measured on the postoperative 10th day.

Intraoperative Interpectoral - Pectoserratus Plane Block

Pain numerical rating scale (numering Rating Scale) at postoperative 1st, 2nd, 6th, 12th and 24th hours in patients, patient recovery scores at 24th hour (QoR15 Turkish version), amount of tramadol used in patient-controlled analgesia, time to first rescue analgesia , adverse events (pneumothorax, nausea, vomiting, pruritus, hematoma, allergic reactions) and hand grip strength on the postoperative 1st day, quality of life, shoulder joint range of motion, and disability level will be measured on the postoperative 10th day.

Non Block

Eligibility Criteria

Age18 Years+
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Sixty patients aged \>18 years old who has breast cancer surgery with intraoperative or preoperative interpectoral - pectoserratus plane block o non block will be included in the study. Patients will be randomly divided into three groups including 20 patients each, postoperative 1st hour.

You may qualify if:

  • Having had a unilateral breast cancer operation
  • Signing the voluntary consent form

You may not qualify if:

  • BMI \>35kg/m2 and \<20kg/m2
  • Having a rheumatological disease (rheumatoid arthritis, etc.),
  • Having neuromuscular disease
  • Having a disease that will add shoulder joint movement (arthritis, prosthesis, fracture sequela, etc.)
  • Having neuropathy, alcoholism, psychiatric disorder
  • Chronic opioid use
  • being pregnant
  • Patient's refusal to use patient-controlled analgesia
  • History of uncontrolled hypertension, diabetes, heart failure, liver failure, kidney failure and/or cerebrovascular disease

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Izmir Bakircay University Cigli Training and Research Hospital

Izmir, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Pain, PostoperativeBreast Neoplasms

Condition Hierarchy (Ancestors)

Postoperative ComplicationsPathologic ProcessesPathological Conditions, Signs and SymptomsPainNeurologic ManifestationsSigns and SymptomsNeoplasms by SiteNeoplasmsBreast DiseasesSkin DiseasesSkin and Connective Tissue Diseases

Study Officials

  • Ömer Faruk Altaş, 1

    İzmir Bakircay University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
10 Days
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Specialist

Study Record Dates

First Submitted

October 2, 2022

First Posted

October 5, 2022

Study Start

October 6, 2022

Primary Completion

January 6, 2023

Study Completion

April 6, 2023

Last Updated

October 5, 2022

Record last verified: 2022-10

Data Sharing

IPD Sharing
Will not share

Locations